Brandon J Webb1,2, Jeff Sorensen3, Al Jephson3, Ian Mecham4, Nathan C Dean3,5. 1. Division of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare, Salt Lake City, UT, USA. 2. Division of Infectious Diseases and Geographic Medicine, Stanford University, Palo Alto, CA, USA. 3. Division of Pulmonary and Critical Care Medicine, Intermountain Healthcare, Salt Lake City, UT, USA. 4. Division of Pulmonary and Critical Care, Utah Valley Regional Medical Center, Intermountain Healthcare, Provo, UT, USA. 5. Division of Pulmonary Medicine, University of Utah, Salt Lake City, UT, USA.
Abstract
QUESTION: Is broad-spectrum antibiotic use associated with poor outcomes in community-onset pneumonia after adjusting for confounders? METHODS: We performed a retrospective, observational cohort study of 1995 adults with pneumonia admitted from four US hospital emergency departments. We used multivariable regressions to investigate the effect of broad-spectrum antibiotics on 30-day mortality, length of stay, cost and Clostridioides difficile infection (CDI). To address indication bias, we developed a propensity score using multilevel (individual provider) generalised linear mixed models to perform inverse-probability of treatment weighting (IPTW) to estimate the average treatment effect in the treated. We also manually reviewed a sample of mortality cases for antibiotic-associated adverse events. RESULTS: 39.7% of patients received broad-spectrum antibiotics, but drug-resistant pathogens were recovered in only 3%. Broad-spectrum antibiotics were associated with increased mortality in both the unweighted multivariable model (OR 3.8, 95% CI 2.5-5.9; p<0.001) and IPTW analysis (OR 4.6, 95% CI 2.9-7.5; p<0.001). Broad-spectrum antibiotic use by either analysis was also associated with longer hospital stay, greater cost and increased CDI. Healthcare-associated pneumonia was not associated with mortality independent of broad-spectrum antibiotic use. In manual review we identified antibiotic-associated events in 17.5% of mortality cases. CONCLUSION: Broad-spectrum antibiotics appear to be associated with increased mortality and other poor outcomes in community-onset pneumonia.
QUESTION: Is broad-spectrum antibiotic use associated with poor outcomes in community-onset pneumonia after adjusting for confounders? METHODS: We performed a retrospective, observational cohort study of 1995 adults with pneumonia admitted from four US hospital emergency departments. We used multivariable regressions to investigate the effect of broad-spectrum antibiotics on 30-day mortality, length of stay, cost and Clostridioides difficile infection (CDI). To address indication bias, we developed a propensity score using multilevel (individual provider) generalised linear mixed models to perform inverse-probability of treatment weighting (IPTW) to estimate the average treatment effect in the treated. We also manually reviewed a sample of mortality cases for antibiotic-associated adverse events. RESULTS: 39.7% of patients received broad-spectrum antibiotics, but drug-resistant pathogens were recovered in only 3%. Broad-spectrum antibiotics were associated with increased mortality in both the unweighted multivariable model (OR 3.8, 95% CI 2.5-5.9; p<0.001) and IPTW analysis (OR 4.6, 95% CI 2.9-7.5; p<0.001). Broad-spectrum antibiotic use by either analysis was also associated with longer hospital stay, greater cost and increased CDI. Healthcare-associated pneumonia was not associated with mortality independent of broad-spectrum antibiotic use. In manual review we identified antibiotic-associated events in 17.5% of mortality cases. CONCLUSION: Broad-spectrum antibiotics appear to be associated with increased mortality and other poor outcomes in community-onset pneumonia.
Authors: Laura Evans; Andrew Rhodes; Waleed Alhazzani; Massimo Antonelli; Craig M Coopersmith; Craig French; Flávia R Machado; Lauralyn Mcintyre; Marlies Ostermann; Hallie C Prescott; Christa Schorr; Steven Simpson; W Joost Wiersinga; Fayez Alshamsi; Derek C Angus; Yaseen Arabi; Luciano Azevedo; Richard Beale; Gregory Beilman; Emilie Belley-Cote; Lisa Burry; Maurizio Cecconi; John Centofanti; Angel Coz Yataco; Jan De Waele; R Phillip Dellinger; Kent Doi; Bin Du; Elisa Estenssoro; Ricard Ferrer; Charles Gomersall; Carol Hodgson; Morten Hylander Møller; Theodore Iwashyna; Shevin Jacob; Ruth Kleinpell; Michael Klompas; Younsuck Koh; Anand Kumar; Arthur Kwizera; Suzana Lobo; Henry Masur; Steven McGloughlin; Sangeeta Mehta; Yatin Mehta; Mervyn Mer; Mark Nunnally; Simon Oczkowski; Tiffany Osborn; Elizabeth Papathanassoglou; Anders Perner; Michael Puskarich; Jason Roberts; William Schweickert; Maureen Seckel; Jonathan Sevransky; Charles L Sprung; Tobias Welte; Janice Zimmerman; Mitchell Levy Journal: Intensive Care Med Date: 2021-10-02 Impact factor: 17.440
Authors: Jessica L Colmerauer; Kristin E Linder; Casey J Dempsey; Joseph L Kuti; David P Nicolau; Anastasia Bilinskaya Journal: Hosp Pharm Date: 2021-11-08
Authors: Barbara Ellen Jones; Jian Ying; Vanessa Stevens; Candace Haroldsen; Tao He; McKenna Nevers; Matthew A Christensen; Richard E Nelson; Gregory J Stoddard; Brian C Sauer; Peter M Yarbrough; Makoto M Jones; Matthew Bidwell Goetz; Tom Greene; Matthew H Samore Journal: JAMA Intern Med Date: 2020-04-01 Impact factor: 21.873
Authors: Jason R Carr; Barbara E Jones; Dave S Collingridge; Brandon J Webb; Caroline Vines; Blake Zobell; Todd L Allen; Rajendu Srivastava; Jenna Rubin; Nathan C Dean Journal: J Rural Health Date: 2020-11-26 Impact factor: 4.333
Authors: Mathias W Pletz; Francesco Blasi; James D Chalmers; Charles S Dela Cruz; Charles Feldman; Carlos M Luna; Julio A Ramirez; Yuichiro Shindo; Daiana Stolz; Antoni Torres; Brandon Webb; Tobias Welte; Richard Wunderink; Stefano Aliberti Journal: Chest Date: 2020-08-25 Impact factor: 9.410
Authors: Chanu Rhee; Sameer S Kadri; John P Dekker; Robert L Danner; Huai-Chun Chen; David Fram; Fang Zhang; Rui Wang; Michael Klompas Journal: JAMA Netw Open Date: 2020-04-01